author-photo

Ian M. Waxman

Bristol-Myers Squibb

33

Papers

9343

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]

2018 European Urology
Show All
- Source
- Cite
- Save
Citations (5)
A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus everolimus in patients (pts) with advanced or metastatic renal cell carcinoma (mRCC) previously treated with antiangiogenic therapy.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (97)
Assessment of nivolumab (Nivo) benefit-risk profile from a 240-mg flat dose versus a 3-mg/kg dosing regimen in patients (Pts) with solid tumors

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (30)
Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab

2016 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (12)
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (67)
Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (35)